Cancer Research UK logo.
SearchDonate
  • Search

A trial of panobinostat with bortezomib, thalidomide and dexamethasone for myeloma that has come back or is no longer responding to treatment (MUK Six)

Overview

Cancer types:

Blood cancers, Myeloma

Status:

Results

Phase:

Phase 1/2

Details

This trial looked at a drug called panobinostat alongside bortezomib, thalidomide and dexamethasone for myeloma.

It was for people whose myeloma had come back or treatment had stopped working.

The trial was open for people to join between 2013 and 2014. The results were published in 2016.

Recruitment start: 31 January 2013

Recruitment end: 29 October 2014

How to join

Please note: In order to you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Professor Jamie Cavenagh

Supported by

Experimental Cancer Medicine Centre (ECMC)

Myeloma UK

Novartis

NIHR Clinical Research Network: Cancer

University of Leeds

Last reviewed: 18 May 2021

CRUK internal database number: 10533

Help and support